Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008968 | 0.92 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1011260 | 0.92 | PTGDR2 (0.46) | PTGDR2TBXA2RPTGDRTAS2R14BMP1 | |
| SCHEMBL1946754 | 0.91 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRTAS2R14CYP3A4 | |
| SCHEMBL1008758 | 0.85 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1944279 | 0.83 | BMP1 (0.47) | PTGDR2TAS2R14BMP1MMP1MMP9 | |
| SCHEMBL1009501 | 0.82 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1062726 | 0.82 | PTGDR2 (0.48) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1009085 | 0.82 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL13580796 | 0.82 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1009159 | 0.81 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRTAS2R14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | claimed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | claimed |
| EP-2268611-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009145989-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | claimed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 7/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.